Gonorrhea Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 4 studies associated with Gonorrhea.
Here is a small sampling of Gonorrhea studies by title:
- The antimicrobial potential of cannabidiol
- J. L. Milton, M.D., (1884). On the Pathology and Treatment of Gonorrhœa. New York: W. Wood & Co.
- Medical Lexicon, A Dictionary of Medical Science, by Robley Dunglison M.D., 1874. Page, 413.
Components of the Gonorrhea Research Dashboard
- Dosing information available for Gonorrhea
- Chemotype guidance for treating Gonorrhea with cannabis
- Synopsis of cannabis research for Gonorrhea
- Individual study details for Gonorrhea
Ready to become a subscriber? Go to our PRICING page.
Gonorrhea Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 4 studies associated with Gonorrhea.
Here is a small sampling of Gonorrhea studies by title:
- The antimicrobial potential of cannabidiol
- J. L. Milton, M.D., (1884). On the Pathology and Treatment of Gonorrhœa. New York: W. Wood & Co.
- Medical Lexicon, A Dictionary of Medical Science, by Robley Dunglison M.D., 1874. Page, 413.
Components of the Gonorrhea Research Dashboard
- Dosing information available for Gonorrhea
- Chemotype guidance for treating Gonorrhea with cannabis
- Synopsis of cannabis research for Gonorrhea
- Individual study details for Gonorrhea
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Gonorrhea
Description of Gonorrhea
Gonorrhea is a curable sexually transmitted infection caused by the gram-negative bacterium Neisseria gonorrhoeae. It is an obligate human pathogen primarily spread through unprotected sexual contact, but an infected mother can also pass the infection to an infant during childbirth, most commonly leading to eye infections in newborns (neonatal conjunctivitis).
In adults, gonorrhea affects mucous membranes in the genitals, reproductive organs, rectum, throat, and, less commonly, the eyes. Many individuals with gonorrhea remain asymptomatic or experience mild symptoms, contributing to unintentional transmission. It is estimated that approximately 10% of infected males and up to 50% of infected females show no noticeable symptoms. When symptoms do occur, they typically appear within a week of exposure but can take up to 30 days to manifest.
The most common manifestation is urethritis in men and cervicitis in women. Both sexes may also experience purulent discharge, pain in the genital or pelvic areas, painful urination, and possible gonococcal infections in the rectum or throat. While rectal infections may cause anal itching, discharge, and discomfort during bowel movements, throat infections are often asymptomatic but can contribute to bacterial transmission.
If left untreated, gonorrhea can lead to severe complications, including pelvic inflammatory disease (PID) in women, increasing the risk of infertility and ectopic pregnancy, while in men, it may cause epididymitis and reduced fertility. In rare cases, gonorrhea can spread to the bloodstream (disseminated gonococcal infection), leading to joint pain, skin lesions, and systemic complications.
Alarmingly, N. gonorrhoeae is developing resistance to multiple antibiotic treatments, with strains now classified as extensively drug-resistant (XDR) gonorrhea. The growing resistance to cephalosporins—the last line of effective treatment—has raised concerns that gonorrhea may become untreatable with currently available antibiotics. This has led to an urgent global effort to develop new antimicrobial therapies, alternative treatment strategies, and vaccine research to combat the rising threat of antibiotic-resistant gonorrhea.
Disease Classification
Condition: GonorrheaDisease Family:
Organ System: Immune System
ICD-10 Chapter: Certain infectious and parasitic diseases
ICD-10 Code: A54.9
Gonorrhea Symptoms:
Burning, painful, and/or itching sensation when urinating, unusual vaginal or penile discharge or pus (white, yellowish, sometimes with an odor), spotting or bleeding between menstrual cycles, vaginal bleed between periods, may progress to pelvic inflammatory disease (in females) and the inflammation of the epididymis and testicles in males (with associated pain and swelling of the groin and scrotum), abscesses along the affected mucous membranes, damage to the reproductive organs, increased risk for ectopic pregnancies and infertility, abdominal pain, pelvic pain, systemic symptoms include fever, septicemia, and inflammation of blood vessels, if left untreated symptoms may spread to the heart valves or joints, in cases of oral infections symptoms may include sore throat and/or swollen lymph nodes around the neck, rectal infections present commonly with rectal itching or pain, and discharge.Also known as:
The clap, Venus's curse, Cupid's itch, sexually transmitted disease (STD), venereal disease (VD), gonorrhoeaDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
